Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 26 '25)

Image
By G.M.

 


    Antiviral Res

  1. ZHU Y, Gao Z, Feng X, Hu Y, et al
    Comprehensive preclinical characterization of IPB29, a pan-coronavirus fusion inhibitor under clinical trials.
    Antiviral Res. 2025;237:106154.
    PubMed         Abstract available

  2. BONNEUX B, Ceconi M, Stobbelaar K, Herschke F, et al
    Insights in the RSV L polymerase function and structure.
    Antiviral Res. 2025;237:106148.
    PubMed         Abstract available

  3. BRUN J, Arman BY, Hill ML, Kiappes JL, et al
    Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
    Antiviral Res. 2025 Feb 23:106123. doi: 10.1016/j.antiviral.2025.106123.
    PubMed         Abstract available

  4. ZIAN D, Iaconis D, Nenci S, Crusco A, et al
    The Efficiency of High-Throughput Screening (HTS) and in-silico data analysis during medical emergencies: identification of effective antiviral 3CLpro inhibitors.
    Antiviral Res. 2025 Feb 18:106119. doi: 10.1016/j.antiviral.2025.106119.
    PubMed         Abstract available


    Eur J Epidemiol

  5. JENSEN CB, Hansen KT, Nielsen CM, Hansen SN, et al
    Cohort profile: The BiCoVac cohort - a nationwide Danish cohort to assess short and long-term symptoms following COVID-19 vaccination.
    Eur J Epidemiol. 2025;40:225-233.
    PubMed         Abstract available


    J Exp Med

  6. MATZ HC, Ellebedy AH
    Vaccination against influenza viruses annually: Renewing or narrowing the protective shield?
    J Exp Med. 2025;222:e20241283.
    PubMed         Abstract available


    J Infect Dis

  7. FURMANSKI M, Murcia PR
    Did horses act as intermediate hosts that facilitated the emergence of 1918 pandemic influenza?
    J Infect Dis. 2025 Apr 22:jiaf197. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  8. LE CTT, Kim K-H, Raha JR, Bhatnagar N, et al
    Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination.
    J Virol. 2025 Apr 23:e0229424. doi: 10.1128/jvi.02294.
    PubMed         Abstract available


    N Engl J Med

  9. UYEKI TM, Dugan VG, Daskalakis DC
    Baloxavir Treatment to Reduce Influenza Virus Transmission.
    N Engl J Med. 2025;392:1652-1654.
    PubMed        

  10. MONTO AS, Kuhlbusch K, Bernasconi C, Cao B, et al
    Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.
    N Engl J Med. 2025;392:1582-1593.
    PubMed         Abstract available


    Pediatrics

  11. BASSETT HK, Rao S, Beck J, Brady PW, et al
    Variability of Clinician Recommendations for Oseltamivir in Children Hospitalized With Influenza.
    Pediatrics. 2025 Apr 25:e2024069111. doi: 10.1542/peds.2024-069111.
    PubMed         Abstract available

  12. ZHU S, Quint J, Penton C, Hoover C, et al
    Duration of Illness in Children <18 Years Dying of Influenza in California: 2004-2023.
    Pediatrics. 2025;155:e2024069368.
    PubMed        


    PLoS Comput Biol

  13. TEOH YC, Noor MS, Aghakhani S, Girton J, et al
    Viral escape-inspired framework for structure-guided dual bait protein biosensor design.
    PLoS Comput Biol. 2025;21:e1012964.
    PubMed         Abstract available

  14. WANG M, Patsenker J, Li H, Kluger Y, et al
    Supervised fine-tuning of pre-trained antibody language models improves antigen specificity prediction.
    PLoS Comput Biol. 2025;21:e1012153.
    PubMed         Abstract available


    PLoS Genet

  15. LIEFFERINCKX C, Stern D, Peree H, Bottieau J, et al
    The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease risk.
    PLoS Genet. 2025;21:e1011599.
    PubMed         Abstract available


    PLoS One

  16. SEDGHIAN A, MohammadEbrahimi S, Sartorius B, Kiani B, et al
    National spatiotemporal patterns of influenza-like illness in Iran: A pre-COVID-19 study (2015-2019).
    PLoS One. 2025;20:e0320990.
    PubMed         Abstract available

  17. TOMKINS AA, Dulai G, Dulai R, Rassenberg S, et al
    Measuring the fitted filtration efficiency of cloth masks, medical masks and respirators.
    PLoS One. 2025;20:e0301310.
    PubMed         Abstract available

  18. ROBINSON CC, Sganzerla D, Manfio JL, Kochhann R, et al
    Incidence, associated factors and impact of the post-COVID-19 condition in Brazil: Study protocol of an observational cohort during the Omicron phase.
    PLoS One. 2025;20:e0322466.
    PubMed         Abstract available

  19. DICKINSON R, Makowski D, van Marwijk H, Ford E, et al
    Interventions for combating COVID-19 misinformation: A systematic realist review.
    PLoS One. 2025;20:e0321818.
    PubMed         Abstract available

  20. VIJAYAKUMAR S, Louis DW, Corneau E, Erqou S, et al
    Association between pre-existing Pulmonary Hypertension and COVID-19 related outcomes in inpatient and ambulatory care settings.
    PLoS One. 2025;20:e0321964.
    PubMed         Abstract available

  21. DI CHIARA C, Ferrarese M, Boracchini R, Cantarutti A, et al
    Long-term neuropsychiatric and neuropsychological impact of the pandemic in Italian COVID-19 family clusters, including children and parents.
    PLoS One. 2025;20:e0321366.
    PubMed         Abstract available

  22. AL-SHAMALI HF, Dong R, Jackson M, Burback L, et al
    Suffering in silence: Accessing mental health care and repetitive transcranial magnetic stimulation (rTMS) for peripartum depression - A qualitative study.
    PLoS One. 2025;20:e0321813.
    PubMed         Abstract available

  23. SHABNAM S, Zaccardi F, Yates T, Islam N, et al
    COVID-19 pandemic and risk factor measurement in individuals with cardio-renal-metabolic diseases: A retrospective study in the United Kingdom.
    PLoS One. 2025;20:e0319438.
    PubMed         Abstract available

  24. SPANYIK A, Simon D, Rigo A, Gacs B, et al
    Cynicism among medical students: An in-depth analysis of mental health dynamics and protective factors in medical education using structural equation modeling.
    PLoS One. 2025;20:e0321274.
    PubMed         Abstract available

  25. BRINKMAN N, Teunis T, Choi S, Ring D, et al
    Factors associated with the presence and intensity of ongoing symptoms in Long COVID.
    PLoS One. 2025;20:e0319874.
    PubMed         Abstract available

  26. BASA M, De Vries J, McDonagh D, Comiskey C, et al
    Adherence to alcohol consumption-related recommendations and predictors of heavy episodic drinking among patients with NCDs during the COVID-19 pandemic.
    PLoS One. 2025;20:e0321577.
    PubMed         Abstract available

  27. SAITO MM, Katayama K, Naruse A, Ruan P, et al
    Effects of inbound attendees of a mass gathering event on the COVID-19 epidemic using individual-based simulations.
    PLoS One. 2025;20:e0321288.
    PubMed         Abstract available

  28. SANCHEZ-IZQUIERDO M, Garcia-Sanchez R, Prieto-Ursua M, Mateos-Nozal J, et al
    Positive outcomes among nursing home caregivers in Spain during the COVID-19 pandemic: A qualitative interview study.
    PLoS One. 2025;20:e0320663.
    PubMed         Abstract available

  29. ABRAR SM, Awasthi N, Smolyak D, Sigalo N, et al
    Auditing the fairness of the US COVID-19 forecast hub's case prediction models.
    PLoS One. 2025;20:e0319383.
    PubMed         Abstract available

  30. DAWSON AJ, Bista A, Wilson AE
    Is trust a zero-sum game? What happens when institutional sources get it wrong.
    PLoS One. 2025;20:e0321743.
    PubMed         Abstract available

  31. SOUCY A, Pellecer Rivera E, Siwek N, Martin L, et al
    Opportunities and challenges within green spaces during COVID-19: Perspectives of visitors and managers in Maine, USA.
    PLoS One. 2025;20:e0320800.
    PubMed         Abstract available

  32. LEBEDEV M, Walsh P, Newman JW, Mutua VN, et al
    Immune mechanisms affected by cyclooxygenase inhibition combined with antiviral treatment in calves infected with bovine respiratory syncytial virus.
    PLoS One. 2025;20:e0321642.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  33. BONTORIN S, Centellegher S, Gallotti R, Pappalardo L, et al
    Mixing individual and collective behaviors to predict out-of-routine mobility.
    Proc Natl Acad Sci U S A. 2025;122:e2414848122.
    PubMed         Abstract available


    Vaccine

  34. HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al
    Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.
    Vaccine. 2025;56:127144.
    PubMed         Abstract available

  35. ZHANG X, Shi H, Ross TM
    Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.
    Vaccine. 2025;56:127156.
    PubMed         Abstract available

  36. FINNEY J, Kuraoka M, Song S, Watanabe A, et al
    Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
    Vaccine. 2025;56:127157.
    PubMed         Abstract available

  37. CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
    Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
    Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
    PubMed         Abstract available

  38. BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
    Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
    Vaccine. 2025;53:127074.
    PubMed         Abstract available

  39. OLESEN SW, Holmdahl I, Ortega-Sanchez IR, Biggerstaff M, et al
    Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.
    Vaccine. 2025;53:127109.
    PubMed         Abstract available

  40. SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al
    Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.
    Vaccine. 2025;53:127091.
    PubMed         Abstract available

  41. SHEARN C, Postavaru GI, Hylton L, Morris H, et al
    COVID-19 vaccine decision-making and the role of institutions across the pandemic in UK Black African and Black Caribbean communities.
    Vaccine. 2025;53:127071.
    PubMed         Abstract available

  42. BERNARD C, Drouin J, Le Vu S, Botton J, et al
    COVID-19 vaccination rates among pregnant women in France: A nationwide cohort study.
    Vaccine. 2025;53:127070.
    PubMed         Abstract available

  43. FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al
    Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
    Vaccine. 2025;53:127084.
    PubMed         Abstract available

  44. FLYNN PM, Stull C, Jain VM, Evans MD, et al
    A national cross-sectional study of dentists' vaccine hesitancy and intention to provide HPV vaccines following emergency COVID-19 vaccination authorization.
    Vaccine. 2025;53:127035.
    PubMed         Abstract available

  45. FELIX P, Melo AA, Costa JP, Colaco M, et al
    Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
    Vaccine. 2025;53:127078.
    PubMed         Abstract available

  46. MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al
    COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis.
    Vaccine. 2025;53:127050.
    PubMed         Abstract available

  47. PATRICK R, Mahale P, Ackerson BK, Hong V, et al
    Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a large, integrated healthcare system in Southern California 2023-2024.
    Vaccine. 2025;53:127033.
    PubMed         Abstract available

  48. FORAN AM, Jetten J, Muldoon OT
    Religious group membership and conspiracy beliefs influence vaccine uptake: Insights from 20 European countries.
    Vaccine. 2025;53:127086.
    PubMed         Abstract available

  49. KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al
    A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
    Vaccine. 2025;53:127063.
    PubMed         Abstract available

  50. MEERAUS W, Postema A, Gray CM, Lee A, et al
    Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
    Vaccine. 2025;53:126955.
    PubMed         Abstract available

  51. ZHAO T, Xu Q, Cai X, Wang M, et al
    Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis.
    Vaccine. 2025;53:126933.
    PubMed         Abstract available

  52. KADOI K, Toba J, Uehara A, Isoda N, et al
    Enhanced sulfate pseudo-affinity chromatography using monolith-like particle architecture for purifying SARS-CoV-2.
    Vaccine. 2025;53:126951.
    PubMed         Abstract available

  53. TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al
    Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
    Vaccine. 2025;53:126932.
    PubMed         Abstract available

  54. KEELING MJ, Hill EM, Petrou S, Tran PB, et al
    Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
    Vaccine. 2025;53:126948.
    PubMed         Abstract available

  55. EYAL N, Wendler D
    Assessing the risks of current COVID-19 challenge trials systematically.
    Vaccine. 2025;53:126877.
    PubMed         Abstract available


    Virus Res

  56. CHEN N, Jin J, Qiao B, Gao Z, et al
    JNK kinase promotes inflammatory responses by inducing the expression of the inflammatory amplifier TREM1 during influenza a virus infection.
    Virus Res. 2025;356:199577.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »